RT info:eu-repo/semantics/article T1 TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status A1 Herreros-Villanueva, Marta A1 Muñiz Rodríguez, Pilar A1 García Girón, Carlos A1 Cavia Saiz, Mónica A1 Coma del Corral, María J. K1 Salud K1 Health K1 Biología molecular K1 Molecular biology AB Background: Although there have been many studies on the p73 gene, some of its functions still remain unclear.There is little research on the relationship between p73 gene transcription and its protein expression and theresponse to certain drugs such as oxaliplatin and cetuximab, which are drugs currently used in colorectal cancer.The purpose of this study was to evaluate the impact of TAp73 expression on oxaliplatin and cetuximab-basedchemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status.Methods: TAp73 was analyzed in three colorectal tumor cell lines HT-29, SW-480 and Caco-2. mRNA TAp73 wasdetermined using Real time PCR; TAp73 protein by immunoblotting and cell viability was analyzed by the MTTmethod.Results: We found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin (in monotherapyor combined with cetuximab) when B-Raf is mutated. This was statistically significant and was also associated withhigher cell viability after the treatment.Conclusions: Here, for the first time we report, that there is a signaling loop between B-Raf activation and p73function.Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of responseto oxaliplatin in monotherapy or combined with cetuximab. PB Springer Nature YR 2010 FD 2010-02 LK http://hdl.handle.net/10259/8072 UL http://hdl.handle.net/10259/8072 LA eng NO We thank B. De La Nogal and the Pharmacy Department for their generous help. Also, we thank CMV and her group in Leon. This work was supported by a grant FIS CA08/00070 from Instituto de Salud Carlos III, Spanish Ministerio de Ciencia e Innovación to MHV and Fundación Burgos por la Investigación de la Salud. MHV is especially thankful to CVP, IHH and AHV, for their support. DS Repositorio Institucional de la Universidad de Burgos RD 24-nov-2024